Terminal Alkyne-Modified DNA Aptamers with Enhanced Protein Binding Affinities.


Journal

ACS chemical biology
ISSN: 1554-8937
Titre abrégé: ACS Chem Biol
Pays: United States
ID NLM: 101282906

Informations de publication

Date de publication:
15 09 2023
Historique:
medline: 18 9 2023
pubmed: 2 8 2023
entrez: 2 8 2023
Statut: ppublish

Résumé

Nucleic acid-based receptors, known as aptamers, are relatively fast to discover and manufacture but lack the diverse functional groups of protein receptors (e.g., antibodies). The binding properties of DNA aptamers can be enhanced by attaching abiotic functional groups; for example, aromatic groups such as naphthalene slow dissociation from proteins. Although the terminal alkyne is a π-electron-rich functional group that has been used in small molecule drugs to enhance binding to proteins through noncovalent interactions, it remains unexplored for enhancing DNA aptamer binding affinity. Here, we demonstrate the utility of the terminal alkyne for improving the binding of DNA to proteins. We prepared a library of 256 terminal-alkyne-bearing variants of HD22, a DNA aptamer that binds the protein thrombin with nanomolar affinity. After a one-step thrombin-binding selection, a high-affinity aptamer containing two alkynes was discovered, exhibiting 3.2-fold tighter thrombin binding than the corresponding unmodified sequence. The tighter binding was attributable to a slower rate of dissociation from thrombin (5.2-fold slower than HD22). Molecular dynamics simulations with enhanced sampling by Replica Exchange with Solute Tempering (REST2) suggest that the π-electron-rich alkyne interacts with an asparagine side chain N-H group on thrombin, forming a noncovalent interaction that stabilizes the aptamer-protein interface. Overall, this work represents the first case of terminal alkynes enhancing the binding properties of an aptamer and underscores the utility of the terminal alkyne as an atom economical π-electron-rich functional group to enhance binding affinity with minimal steric perturbation.

Identifiants

pubmed: 37531184
doi: 10.1021/acschembio.3c00183
doi:

Substances chimiques

Aptamers, Nucleotide 0
Alkynes 0
Thrombin EC 3.4.21.5

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1976-1984

Subventions

Organisme : NCRR NIH HHS
ID : S10 RR013790
Pays : United States

Auteurs

Eric M Kohn (EM)

Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.

Kirill Konovalov (K)

Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
Theoretical Chemistry Institute, Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.

Christian A Gomez (CA)

Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.

Gillian N Hoover (GN)

Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.

Andrew Kai-Hei Yik (AK)

Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
Theoretical Chemistry Institute, Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.

Xuhui Huang (X)

Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
Theoretical Chemistry Institute, Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.

Jeffrey D Martell (JD)

Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53705, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH